Acute Lymphoblastic Leukemia, in Relapse Clinical Trials

37 clinical trials for Acute Lymphoblastic Leukemia, in Relapse across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Determining the Mechanisms of Loss of CAR T Cell Persistence — RECRUITING
• Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia — RECRUITING · PHASE1
• Venetoclax Basket Trial for High Risk Hematologic Malignancies — RECRUITING · PHASE1
• Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients — RECRUITING · NA
• CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies — RECRUITING · PHASE1
• Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial — RECRUITING · PHASE1
• CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction — RECRUITING · NA
• A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies — RECRUITING · PHASE1
• Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies — RECRUITING · PHASE1
• Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies — RECRUITING · PHASE1
• HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies — RECRUITING · PHASE1
• HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies — RECRUITING · PHASE1
• Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). — RECRUITING · PHASE1
• Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL — RECRUITING · PHASE1
• Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence — RECRUITING · PHASE1
• CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies — RECRUITING · PHASE1
• Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) — COMPLETED
• CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL — TERMINATED · PHASE1
• Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL — NOT_YET_RECRUITING · PHASE1
• Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia — COMPLETED · PHASE1
• Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children — COMPLETED · PHASE2
• Study of Anti-CD22 CAR-T Cells Treating Leukemia Children — COMPLETED · PHASE2
• Study of Sequential CAR-T Cell Treating Leukemia Children — TERMINATED · PHASE2
• Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL — NOT_YET_RECRUITING · PHASE1
• HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies — WITHDRAWN · PHASE1
• Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO — OTHER
• CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children — COMPLETED · PHASE2
• International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia — TERMINATED · PHASE1
• Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT — COMPLETED · PHASE1
• GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia — COMPLETED · PHASE2
• Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD — OTHER · PHASE4
• Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT — OTHER · PHASE1
• Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL — OTHER · PHASE1
• Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia — TERMINATED · PHASE1

Refine this search